PreveCeutical completes efficacy screening of small interfering RNA-based therapy for type 2 diabetes

PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF) has completed efficacy screening of its small interfering RNA (siRNA) gene silencing therapy as a treatment for type 2 diabetes and obesity. 

The treatment works by targeting a specific gene of interest responsible for the overproduction of a protein molecule that has been identified as responsible for causing diabetes and obesity.

Earlier this year, the company identified a panel of siRNA constructs and worked to chemically transform them into what it calls “smart siRNAs” that work to essentially turn off the gene of interest.

READ: PreveCeutical makes good progress with non-addictive painkiller research program

On Monday, PreveCeutical announced that it has completed screening of its smart siRNAs. The company found that smart siRNA’s gene silencing potency was retained and comparable to that of the original siRNAs, meaning the chemical modifications made by the company did not reduce efficacy.

“We are pleased with the latest Smart-siRNA screening results, which show a great promise in retention of the siRNA’s stability and no apparent changes in their potency. We look forward to further progressing our dual gene therapy research program.”

Biostability is essential for the company as it looks ahead towards assessment in preclinical mice models of type 2 diabetes and obesity

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Story by ProactiveInvestors